Bristol-Myers Squibb (BMY) revenue breakdown
By product, Eliquis is the largest at 30% of fiscal 2025 revenue; Yervoy grew fastest, 11% a year over 3 years.
By region, United States is the largest at 69% of fiscal 2025 revenue, growing 14% a year over 8 years.
Revenue by product
Fiscal years, as Bristol-Myers Squibb reports them in its 10-K filings; fiscal 2025 total $48.2B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Eliquis | — | — | — | — | — | $11.8B | $12.2B | $13.3B | $14.4B | 30% |
| Opdivo | — | — | — | — | — | $8.2B | $9.0B | $9.3B | $10.0B | 21% |
| Orencia | — | — | — | — | — | $3.5B | $3.6B | $3.7B | $3.7B | 8% |
| Revlimid | — | — | — | — | — | $10.0B | $6.1B | $5.8B | $3.0B | 6% |
| Yervoy | — | — | — | — | — | $2.1B | $2.2B | $2.5B | $2.9B | 6% |
| Pomalyst/Imnovid | — | — | — | — | — | $3.5B | $3.4B | $3.5B | $2.7B | 6% |
| Reblozyl | — | — | — | — | — | $717M | $1.0B | $1.8B | $2.3B | 5% |
| Other Growth products | — | — | — | — | — | $1.1B | $1.2B | $1.6B | $1.9B | 4% |
| Breyanzi | — | — | — | — | — | $182M | $364M | $747M | $1.4B | 3% |
| Opdualag | — | — | — | — | — | $252M | $627M | $928M | $1.2B | 2% |
| Camzyos | — | — | — | — | — | $24M | $231M | $602M | $1.1B | 2% |
| Other Legacy products | — | — | — | — | — | $1.2B | $962M | $925M | $798M | 2% |
| Zeposia | — | — | — | — | — | $250M | $434M | $566M | $577M | 1% |
| Sprycel | — | — | — | — | — | $2.2B | $1.9B | $1.3B | $493M | 1% |
| Abecma | — | — | — | — | — | $388M | $472M | $406M | $427M | 1% |
| Abraxane | — | — | — | — | — | $811M | $1.0B | $875M | $368M | 1% |
| Sotyktu | — | — | — | — | — | $8M | $170M | $246M | $291M | 1% |
| Opdivo Qvantig | — | — | — | — | — | — | — | — | $238M | 0% |
| Krazati | — | — | — | — | — | — | — | $126M | $205M | 0% |
| Cobenfy | — | — | — | — | — | — | — | $10M | $155M | 0% |
| Net product sales | — | — | — | — | $45.1B | — | — | — | — | — |
| Revlimid | — | — | $1.3B | $12.1B | — | — | — | — | — | — |
| Eliquis | $4.9B | $6.4B | $7.9B | $9.2B | — | — | — | — | — | — |
| Opdivo | $4.9B | $6.7B | $7.2B | $7.0B | — | — | — | — | — | — |
| Orencia | $2.5B | $2.7B | $3.0B | $3.2B | — | — | — | — | — | — |
| Pomalyst/Imnovid | — | — | $322M | $3.1B | — | — | — | — | — | — |
| Mature and other brands | $3.9B | $2.4B | $2.3B | $2.2B | — | — | — | — | — | — |
| Sprycel | $2.0B | $2.0B | $2.1B | $2.1B | — | — | — | — | — | — |
| Yervoy | $1.2B | $1.3B | $1.5B | $1.7B | — | — | — | — | — | — |
| Abraxane | — | — | $166M | $1.2B | — | — | — | — | — | — |
| Baraclude | $1.1B | $744M | — | — | — | — | — | — | — | — |
| Alliance revenues | — | — | — | — | $716M | — | — | — | — | — |
| Other revenues | — | — | — | — | $614M | — | — | — | — | — |
| Empliciti | $231M | $247M | $357M | $381M | — | — | — | — | — | — |
| Reblozyl | — | — | — | $274M | — | — | — | — | — | — |
| Inrebic | — | — | $5M | $55M | — | — | — | — | — | — |
| Onureg | — | — | — | $17M | — | — | — | — | — | — |
| Zeposia | — | — | — | $12M | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Bristol-Myers Squibb reports them in its 10-K filings; fiscal 2025 total $48.2B.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $11.4B | $12.6B | $15.3B | $26.6B | $29.2B | $31.5B | $31.2B | $34.1B | $33.3B | 69% |
| International | $5.0B | $5.7B | $6.3B | $15.3B | $16.3B | $13.8B | $13.1B | $13.2B | $13.8B | 29% |
| Other | $553M | $584M | $524M | $631M | $852M | $834M | $699M | $996M | $1.1B | 2% |
| Rest of World | $3.9B | $3.7B | $4.0B | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BMY.
Open BMY in InvestinglyQuestions
Where does Bristol-Myers Squibb make its money?
In fiscal 2025, by product: Eliquis $14.4B, Opdivo $10.0B, Orencia $3.7B, Revlimid $3.0B, Yervoy $2.9B.
From Bristol-Myers Squibb's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.